See the DrugPatentWatch profile for tigecycline

Based on the information available, there is no definitive answer to whether tigecycline is more effective than carbapenems in treating B fragilis infections. However, some studies and sources provide insightful information on this topic.

Tigecycline is a broad-spectrum antibiotic, while carbapenems are a class of beta-lactam antibiotics often used to treat severe or drug-resistant infections [1]. Both have been used to treat B fragilis infections, an anaerobic bacterium that can cause various diseases, including intra-abdominal and gynecological infections [2].

A study published in the Journal of Antimicrobial Chemotherapy in 2010 compared the in vitro activities of tigecycline and carbapenems against B fragilis isolates [3]. The study found that tigecycline had comparable activity to carbapenems against B fragilis isolates. However, the study did not assess the clinical efficacy of these antibiotics in treating B fragilis infections.

Another study published in Clinical Infectious Diseases in 2012 evaluated the clinical and microbiological responses of tigecycline and carbapenems in treating intra-abdominal infections caused by B fragilis [4]. The study found no significant difference in the clinical and microbiological responses between tigecycline and carbapenems.

It is important to note that tigecycline has a black box warning from the U.S. Food and Drug Administration (FDA) for increased mortality in patients with severe intra-abdominal infections [5]. Therefore, carbapenems are generally preferred over tigecycline in treating severe or life-threatening infections caused by B fragilis.

In summary, based on the available information, there is no clear evidence that tigecycline is more effective than carbapenems in treating B fragilis infections. Both antibiotics have comparable in vitro activities against B fragilis isolates. However, carbapenems are generally preferred over tigecycline due to the black box warning and their efficacy in treating severe infections.

Sources:
[1] <https://www.ncbi.nlm.nih.gov/books/NBK77160/>
[2] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660142/>
[3] <https://academic.oup.com/jac/article/65/5/935/840786>
[4] <https://academic.oup.com/cid/article/54/5/622/3043204>
[5] <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s011s012lbl.pdf>